P
ETON icon

&Partners’s Eton Pharmaceutcials ETON Stock Holding History

&Partners’s Portfolio ETON Stock Details ETON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$362K Buy
+10,000
New +$293K ﹤0.01% 2026

Other funds holding ETON

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $6.92B AUM 24.7% 1-Year Est. Return

&Partners's ETON Position: Q2 2026 in Review

&Partners opened a new position in Eton Pharmaceutcials (ETON) in Q2 2026: 10,000 shares worth $362K. The stake represents ﹤0.01% of the portfolio and ranks #2026 among its holdings.

165 funds tracked by Wall St. Rank hold ETON as of Q2 2026.

  • &Partners held 10,000 shares of Eton Pharmaceutcials worth $362K as of Q2 2026.
  • Eton Pharmaceutcials was a new &Partners position in Q2 2026.
  • Eton Pharmaceutcials made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2026 holding.
  • 165 funds tracked by Wall St. Rank held Eton Pharmaceutcials as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.